View Older Stories
-
DexCom (DXCM) PT Lowered to $82 at Canaccord
-
DexCom (DXCM) PT Lowered to $80 at BofA Securities
-
Piper Sandler on DexCom (DXCM): 'Well Done Investor Meeting Provides Excellent Stock Setup'
-
Truist on DexCom (DXCM): 'Catalyst Rich 27-28 Ahead'
-
DexCom (DXCM) Reiterated at Buy by Benchmark After Investor Event
-
After-hours movers: AMAT, FIG, DXCM, DLO, STNE, PZZA
-
Dexcom adds two directors, expands board committee following Elliott talks
-
TD Cowen Reiterates Buy Rating on DexCom (DXCM)
-
Benchmark Starts DexCom (DXCM) at Buy
-
DexCom (DXCM) PT Raised to $100 at Canaccord
-
DexCom (DXCM) PT Lowered to $77 at Bernstein SocGen Group
-
DexCom (DXCM) PT Lowered to $75 at Mizuho
-
DexCom (DXCM) Tops Q1 EPS by 9c; offers guidance
-
TD Cowen Highlights a 'Compelling 2026-2028 Margin Story' at DexCom (DXCM)
-
Evercore ISI Upgrades DexCom (DXCM) to Outperform, 'Turning the page to T2 NIT expansion'
-
Piper Sandler: 'When Will Things Turn in Med Tech and What Names to Own Now?'
-
DexCom (DXCM) PT Lowered to $95 at Canaccord Genuity
-
Stifel Reiterates Buy Rating on DexCom (DXCM)
-
DexCom (DXCM) Tops Q4 EPS by 3c ; Offers Guidance
-
Piper Sandler on DexCom (DXCM): 'Encouraged About the Stock Setup Over the Long-Term'
-
Jefferies on DexCom (DXCM): 'We think the '26 guide is conservative, leaving room for upside in stock'
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
Barclays Downgrades DexCom (DXCM) to Underweight
-
Morgan Stanley Reiterates Overweight Rating on DexCom (DXCM), 'Prelim Results Likely Clear the Bar'
-
Citi Opens 90-Day Upside Catalyst Watch on DexCom (DXCM)
-
Dexcom reports Q4 revenue of $1.26 billion, provides 2026 outlook
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Goldman: 'Top Call Buying Opportunities for 2026'
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
Raymond James Reiterates Strong Buy Rating on Jabil (JBL)
-
DexCom (DXCM) PT Raised to $92 at Leerink Partners
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
DexCom (DXCM) Added to Citi 90-Day Upside Catalyst Watch List
-
Evercore ISI Starts DexCom (DXCM) at In Line
-
Dexcom launches 15-day glucose monitor in US on Dec. 1
-
Dexcom receives FDA clearance for basal insulin dosing optimizer
-
'DexCom (DXCM) Too Cheap to Ignore'; Stock PT Lowered at Bernstein
-
This medtech stock is "objectively too cheap," BofA says
-
DexCom (DXCM) PT Lowered at Piper Sandler; 'We Strongly Recommend Investors Buy the Stock'
-
DexCom (DXCM) PT Lowered to $85 at BTIG
-
DexCom (DXCM) PT Lowered to $99 at Canaccord Genuity
-
DexCom (DXCM) Tops Q3 EPS by 4c ; Offers Guidance
-
DexCom (DXCM) call put ratio 3.2 calls to 1 put with a focus on October 31 weekly 75 and 80 calls
-
DexCom (DXCM) Mentioned Cautiously Again at Hunterbrook
-
TD Cowen on DexCom (DXCM): 'G7 Angst Has Created Attractive Risk/Reward Setup Into Q3 Print'
-
Piper Sandler Sees Good Setup for DexCom (DXCM) Stock, Recommends Purchase
-
Stifel Resumes DexCom (DXCM) at Buy
-
TD Cowen on DexCom (DXCM): ' G7 Issues Are Mostly Resolved, Limiting Share Shifts'
-
UBS Reiterates Buy Rating on DexCom (DXCM) Following Over 10% Selloff
-
DexCom (DXCM) Mentioned as short at Hunterbrook

